Femasys Inc. (NASDAQ:FEMY – Get Rating) shares rose 8.5% during mid-day trading on Friday . The stock traded as high as $1.12 and last traded at $1.12. Approximately 2,795 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 168,899 shares. The stock had previously closed at $1.03.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on the stock. HC Wainwright cut their price target on shares of Femasys from $8.00 to $5.00 and set a "buy" rating for the company in a report on Thursday, October 20th. Chardan Capital cut their price target on shares of Femasys from $15.00 to $12.00 and set a "buy" rating for the company in a report on Friday, November 11th.
Get
Femasys alerts:
Femasys Stock Performance
The company has a market cap of $13.23 million, a PE ratio of -1.42 and a beta of -0.31. The firm's fifty day moving average is $1.20 and its 200 day moving average is $1.59. The company has a current ratio of 9.56, a quick ratio of 9.37 and a debt-to-equity ratio of 0.01.
Institutional Investors Weigh In On Femasys
A number of large investors have recently modified their holdings of FEMY. Vanguard Group Inc. purchased a new stake in shares of Femasys during the first quarter worth $269,000. CM Management LLC grew its holdings in shares of Femasys by 33.3% during the second quarter. CM Management LLC now owns 300,000 shares of the company's stock worth $723,000 after buying an additional 75,000 shares in the last quarter. UBS Group AG grew its holdings in shares of Femasys by 6,394.8% during the first quarter. UBS Group AG now owns 66,702 shares of the company's stock worth $151,000 after buying an additional 65,675 shares in the last quarter. Clear Creek Financial Management LLC grew its holdings in shares of Femasys by 74.7% during the second quarter. Clear Creek Financial Management LLC now owns 150,801 shares of the company's stock worth $363,000 after buying an additional 64,500 shares in the last quarter. Finally, Royal Bank of Canada grew its holdings in shares of Femasys by 2,381.2% during the first quarter. Royal Bank of Canada now owns 55,158 shares of the company's stock worth $125,000 after buying an additional 52,935 shares in the last quarter. Hedge funds and other institutional investors own 6.87% of the company's stock.
Femasys Company Profile
(Get Rating)
Femasys Inc, a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing.
Featured Articles
- Get a free copy of the StockNews.com research report on Femasys (FEMY)
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.
